High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.
Shingles is no minor inconvenience. Ask anyone who has had it and they will tell you the burning, nerve-rattling pain can last for days. But what if surviving shingles was only half the battle? New research suggests the virus behind it could raise your risk of stroke and dementia years after the ...
The stock market rode a big rally in software stocks to fresh highs on Thursday despite another hot inflation report. The Nasdaq gained 0.9%. The Dow rose 25 points to post a slight gain and eke out a fresh record, too.
Eli Lilly shares are on pace to hit a new all-time closing high on news of increased insurance coverage for its blockbuster weight-loss drug Zepbound. Lilly shares were recently up 4.4% to $1,130.90. Pharmacy-benefit manager CVS Caremark decided to add back Lilly’s Zepbound weight-loss drug to its lists of preferred drugs.
Small biotech firms "latch onto" AI more quickly than bigger firms, the head of Chinese tech giant Tencent's healthcare division said on Thursday, as more businesses embrace AI to improve efficiency. Pharmaceutical companies are also increasingly turning to AI to accelerate research and development, betting on new modeling tools and automated labs to improve efficiency and slash costs as well as drug development timelines. Drugmakers including Novo Nordisk and Eli Lilly have announced AI-related collaborations with technology firms.
May 28 () - CVS Health said on Thursday it will add Eli Lilly's weight-loss drug Zepbound back to some of its drug lists as an additional preferred option for insurance coverage. Caremark, CVS' pharmacy benefit management unit, had dropped Zepbound from coverage on July 1 last year, while continuing to reimburse for rival Novo Nordisk's Wegovy after negotiating a more favorable price from the Danish drugmaker.
Apogee Therapeutics revealed mixed results for its experimental eczema treatment Wednesday, and the stock dropped.
Pharmaceutical companies have spent years targeting a common blood particle associated with heart-attack risks.
By Rishika Sadam and Sai Ishwarbharath B HYDERABAD/BENGALURU, May 27 (Reuters) - U.S. carrier American Airlines Group plans to double headcount at its India technology hub to about 800 by early next
Eli Lilly agreed to buy three vaccine developers targeting shingles, bacterial infections and Epstein-Barr Virus.
(Bloomberg) -- Eli Lilly & Co. is on a record spending spree, announcing acquisitions worth more than $20 billion so far in 2026 as the drugmaker expands beyond its blockbuster obesity franchise. Most Read from BloombergIran’s Khamenei Says No Going Back for Middle East Rocked by WarUS Strikes Targets in Iran Even as Trump Hails Progress on DealRussia Tells US to Evacuate Its Diplomats and Citizens From KyivThese AI Gurus Are Charging Wall Street Banks $25,000 a DayPutin Signs Law on Use of Army
Eli Lilly and Co (NYSE:LLY) has announced agreements to acquire three vaccine developers, Curevo, LimmaTech Biologics AG, and Vaccine Company, in transactions valued at up to $3.83 billion combined, as the company expands its research and development efforts into infectious disease...
After a brief cool-off last week, U.S. semiconductor and memory stocks are rallying in Tuesday morning trading, led by Micron, which traded above a $1 trillion market capitalization for the first time.
Eli Lilly acquired three infectious diseases companies for up to $3.83 billion. Lilly stock ticked higher in response.
Eli Lilly announced deals to acquire three biotechnology companies, Curevo, LimmaTech Biologics, and Vaccine Company for roughly $3.8 billion in total consideration.
The deals give Lilly vaccines targeting shingles, bacterial pathogens, and Epstein-Barr virus as it expands beyond weight loss drugs
Eli Lilly agreed to acquire three vaccine developers in deals worth up to nearly $4 billion combined, the company told The Wall Street Journal. Indianapolis-based Lilly has agreed to acquire Curevo, LimmaTech Biologics and Vaccine Co. Curevo is developing a shingles vaccine that Lilly believes could be as effective as the current standard but with reduced side effects, said Daniel Skovronsky, Lilly’s chief scientific and product officer.
(Bloomberg) -- US equity futures extended gains and Treasuries rallied as investors remained hopeful that the latest American strikes on Iran won’t derail talks to end the Middle East conflict. Most Read from BloombergNvidia CEO Urges Super Micro to Tighten Up on ComplianceTrump Doctor Visit Renews Health Scrutiny as 80th Birthday NearsTrump Says He’ll Announce Negotiated Deal With Iran ShortlyRubio Sees Good News Coming on Hormuz as Iran Talks ContinueUS, Iran Inch Toward Deal as Gaps Remain on
A suite of new studies suggest drugs such as Ozempic and Zepbound might slow tumor progression and improve survival, but more research is needed to confirm the findings.
The deal is Lilly's seventh acquisition of 2026 and centers on Engage's non-viral DNA delivery platform, Tethosome
An investigational drug developed by Eli Lilly delivered clinically meaningful weight loss in a trial, the company said as it looks expand its obesity treatment portfolio amid soaring demand.
The healthcare team covers Q1 results from pharma and medtech companies and provides a wrap-up of the key takeaways.
LONDON/NEW YORK, May 21 (Reuters) - Lower prices for weight-loss pills from Novo Nordisk and Eli Lilly are prompting patients to switch from compounded medications to branded Wegovy and Foundayo, according to Reuters interviews with nine U. Prices for the lowest doses of both Novo's oral Wegovy and Lilly's Foundayo tend to be lower than for their injected obesity medicines, and at par with those offered by pharmacies that mix the ingredients themselves and make compounded versions.
Elon Musk could pass an unthinkable wealth threshold, becoming the world’s first trillionaire, depending on investors’ excitement for SpaceX shares when it goes public. If the company surpasses a valuation of about $1.7 trillion, then Musk’s slightly more than 40% stake, combined with his Tesla shares, would make him the first man with a net worth eclipsing 13 figures. The calculation omits restricted shares that SpaceX has granted to Musk, but which haven’t been earned, though it includes options he could exercise shortly.
Novo Nordisk-linked pharmaceutical strength helped Denmark post a fourth straight quarter of economic expansion.
These stocks have declined this year, while the consensus estimates for the companies’ earnings per share have soared.
Bristol Myers Squibb said on Wednesday it is partnering with Anthropic to make its Claude AI model available to over 30,000 employees in an effort to accelerate the discovery, development and delivery of new medicines. • Bristol said it will also leverage Claude Code, Anthropic's coding tool, and evaluate its use in research, drug development, manufacturing and other commercial and medical affairs. • Agentic AI, which requires little human intervention, could increase clinical development productivity by about 35% to 45% over the next five years, consultancy McKinsey said last year.
(Bloomberg) -- The way Unilever Plc Chief Executive Officer Fernando Fernandez starts every meeting at the consumer products maker says a lot about the mindset of corporate bosses who fear their companies have lost their edge.Most Read from BloombergUS Lawmakers Plan New $130 Fee for Electric Vehicle OwnersNATO Is Starting to Consider Hormuz Mission to Protect ShipsHasbro Cancels Dungeons & Dragons Game From ‘Star Wars’ VeteranUS 30-Year Yield Hits Highest Since 2007 as Selloff DeepensTrump Thre
Dell stock received two price-target hikes after the company detailed its strategy to capitalize on the AI megatrend.
Emerging research shows there are ‘super-responders’ to GLP-1 drugs, and others who don’t respond at all.
We use Google Analytics to count anonymous page views and understand which content gets read. No ads, no profiles. Decline keeps you on cookieless mode. Details.
